Effect of Repaglinide Addition to NPH Insulin Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
- Daniel Antonio de Luis, MD ,
- Rocío Aller, MD ,
- Luis Cuellar, PHD ,
- Concepción Terroba, PHD ,
- Hilda Ovalle, PHD ,
- Olatz Izaola, PHD and
- Enrique Romero, MD
- Instituto de Endocrinología y Nutrición, Facultad de Medicina y Hospital Rio Hortega, Universidad de Valladolid, Valladolid, Spain
Repaglinide is a new type of oral hypoglycemic agent. Its rapid absorption, short metabolic half-time (1 h), and novel insulin release profile are all characteristics desired for treating elderly people with type 2 diabetes. The aim of this study was to investigate the efficacy and safety of repaglinide in combination with NPH insulin in subjects with type 2 diabetes on insulin monotherapy with suboptimal glycemic control.
The prospective, no-blind study was performed in our clinical research unit. We selected 27 (7 men and 20 women) type 2 diabetic patients who were nonsmokers and whose glycemic control was unsatisfactory (HbA1c >7.1%) with two doses of NPH insulin for >6 months. Additional inclusion criteria were age 45–75 years (mean 65 ± 9.6) and BMI >21 kg/m2 (mean 27.2 ± 3.9). For the purpose of this study, we followed the American Diabetes Association’s standards for medical care, which considers an HbA1c level <1% above the upper reference range for a nondiabetic population as a goal for good glycemic control and an HbA1c level >7.1% as unsatisfactory glycemic control. All subjects were required to be able to comply with the protocol and to carry out home blood glucose …
